ACE gene sequence and nucleotide variants in IgA nephropathy

Singapore Medical Journal

Volumn 52, Issue 11, 2011, Pages 824-834

  Woo, K T ^a   Lau, Y K ^a   Chan, C M ^a   Zhao, Y ^a   Tan, H B ^a   Liu, F E ^a   Fook Chong, S ^a   Wong, K S ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

Haplotypes; IgA nephropathy; Renal failure; Single nucleotide polymorphism

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LOSARTAN;

ADULT; ANGIOTENSIN CONVERTING ENZYME GENE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; FEMALE; GENE; GENE EXPRESSION PROFILING; GENE FREQUENCY; GENE IDENTIFICATION; GENE SEQUENCE; HAPLOTYPE; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY FAILURE; KIDNEY FUNCTION; MALE; PROGNOSIS; PROTEIN URINE LEVEL; RENAL PROTECTION; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; BLOOD PRESSURE; FEMALE; GENETIC VARIATION; GENOTYPE; GLOMERULONEPHRITIS, IGA; HAPLOTYPES; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NUCLEOTIDES; PEPTIDYL-DIPEPTIDASE A; PROGNOSIS; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 81055139009     PISSN: 00375675     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. D' Amico G. Natural history of idiopathic IgA nephropathy and factors meditative of disease outcome. Semin Nephrol 2004; 24:179-96.
2. Nair R, Walker PD. Is IgA nephropathy the commonest primary glomerulopathy among young adults in the USA? Kidney Int 2006;69:1455-8.
3. Woo KT, Lau YK, Choong LH, et al. IgA nephropathy: effects of clinical indices, ACEI/ATRA therapy and ACE gene polymorphism on disease progression. Nephrol 2002; 7:S166-72.
4. Berger J. IgA glomerular deposits in renal disease. Transplant Proc 1969; 1:939-44.
5. Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 1986; 77:1993-2000.
6. Hannedouche T, Landais P, Goldfarb B, et al. Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure. BMJ 1994; 309:833-7.
7. Maschio G, Alberti D, Janin G, et al. Effect of the angiotensinconverting- enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Eng J Med 1996; 334:939-45.
8. Harden PN, Geddes C, Rowe PA, et al. Polymorphisms in angiotensin-convertingenzyme gene and progression of IgA nephropathy. Lancet 1995; 345:1540-2.
9. Rigat B, Hubert C, Alhenc-Gelas F, et al. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990; 86:1343-6.
10. Ohishi M, Rakugi H, Ogihara T. Association between a deletion polymorphism of the angiotensin-converting enzyme gene and left ventricular hypertrophy. N Engl J Med 1994; 331:1097-8.
11. Vleming LJ, van der Pijl JW, Lemkes HH, et al. The DD genotype of the ACE gene polymorphism is associated with progression of diabetic nephropathy to end stage renal failure in IDDM. Clin Nephrol 1999; 51:133-40.
12. Perna A, Ruggenenti P, Testa A, et al. ACE genotype and ACE inhibitors induced renoprotection in chronic proteinuric nephropathies. Kidney Int 2000; 57:274-81.
13. Narita I, Goto S, Saito N, et al. Angiotensinogen gene variation and renoprotective efficacy of renin-angiotensin system blockade in IgA nephropathy. Kidney Int 2003; 64:1050-8.
14. Kehoe PG, Katzov H, Feuk L, et al. Haplotypes extending across ACE are associated with Alzheimer's disease. Hum Mol Genet 2003; 12:859-67.
15. Weir BS. Genetic Data Analysis II. 1st Edition. Boston: Sinauer Associates, Sunderland, 1996.
16. Tiret L, Cambien F. Departure from Hardy-Weinberg equilibrium should be systemically tested in studies of association between genetic markers and disease. Circulation 1995; 92:3364-5.
17. Hartl DL, Clark AG. Principles of population genetics. 3rd edition. Boston: Sinauer Associates, Sunderland, 1997: 59.
18. Clark AG. Inference of haplotypes from PCR-amplified samples of diploid populations. Mol Biol Evol 1990; 7:111-22.
19. Rieder MJ, Taylor SL, Clark AG, Nickerson DA. Sequence variation in the human angiotensin converting enzyme. Nat Genet 1999; 22:59-62.
20. Vleming LJ, van Kooten C, van Dijk M, et al. The D-allele of the ACE gene polymorphism predicts a stronger antiproteinuric response to ACE inhibitors. Nephrol 1998; 4:143-9.
21. Sebastiani P, Lazarus R, Weiss ST, et al. Minimal haplotype tagging. Proc Natl Acad Sci U S A 2003; 100:9900-5.
22. Keavney B, McKenzie CA, Connell JM, et al. Measured haplotype analysis of angiotensin-I converting enzyme gene. Hum Mol Genet 1998; 7:1745-51.
23. Kamatani N, Sekine A, Kitamoto T, et al. Large-scale singlenucleotide polymorphism (SNP) and haplotype analyses, using dense SNP Maps, of 199 drug-related genes in 752 subjects: the analysis of the association between uncommon SNPs within haplotype blocks and the haplotypes constructed with haplotypetagging SNPs. Am J Hum Genet 2004; 75:190-203.
24. Bantis C, Ivens K, Kreusser W, et al. Influence of genetic polymorphisms of the reninangiotensin system on IgA nephropathy. Am J Nephrol 2004; 24:258-67.
25. Yoon HJ, Kim H, Kim HL, et al. Interdependent effect of angiotensin-converting enzyme and platelet-activating factor acetylhydrolase gene polymorphisms on the progression of immunoglobulin A nephropathy. Clin Genet 2002; 62:128-34.
26. Nonoguchi H, Nakayama Y, Shiigai T, et al. Low-responders to angiotensin II receptor blockers and genetic polymorphism in angiotensin-converting enzyme. Clin Nephrol 2007; 68:209-15.
27. Ng DP, Tai BC, Koh D, Tan KW, Chia KS. Angiotensin-I converting enzyme insertion/deletion polymorphism and its association with diabetic nephropathy: a metaanalysis of studies reported between 1994 and 2004 and comprising 14,727 subjects. Diabetologia 2005; 48:1008-16.
28. Seki N, Hashimoto N, Suzuki Y, Yagui K, Saito Y. Differential effects of RAS inhibitors associated with ACE gene polymorphisms in type 2 diabetic nephropathy. Diabetes Res Clin Pract 2006; 72:135-41.
29. Woo KT, Lau YK, Chan CM, Wong KS. Angiotensin-converting enzyme inhibitor versus angiotensin 2 receptor antagonist therapy and the influence of angiotensinconverting enzyme gene polymorphism in IgA nephritis. Ann Acad Med Singapore; 2008: 37:372-6.
30. Lau YK, Woo KT, Choong HL, et al. ACE gene polymorphism and disease progression of IgA nephropathy in Asians in Singapore. Nephron 2002; 91:499-503.
31. Draman CR, Kong NC, Gafor AH, et al. The effects of angiotensinconverting enzyme gene polymorphism on the progression of immunoglobulin A nephropathy in Malaysian patients. Singapore Med J 2008; 49:924-9.
32. Woo KT, Chan CM, Tan HK, et al. Beneficial effects of high dose losartan in IgA nephritis Clin Nephrol 2009; 71:617-24.
33. Woo KT, Chan CM, Choong HL, et al. High dose Losartan and ACE gene polymorphism in IgA nephritis. Genomic Med 2008; 2:83-91.